Neuroprotection in multiple sclerosis

Clin Neurol Neurosurg. 2006 Mar;108(3):250-4. doi: 10.1016/j.clineuro.2005.11.007. Epub 2006 Jan 4.


In chronic inflammatory diseases like multiple sclerosis (MS), neuroprotection refers to strategies aimed at prevention of the irreversible damage of various neuronal and glial cell populations, and promoting regeneration. It is increasingly recognized that MS progression, in addition to demyelination, leads to substantial irreversible damage to, and loss of neurons, resulting in brain atrophy and cumulative disability. One of the most promising neuroprotective strategies involves the use of bone marrow derived stem cells. Both hematopoietic and non-hematopoietic (stromal) cells can, under certain circumstances, differentiate into cells of various neuronal and glial lineages. Neuronal stem cells have also been reported to suppress EAE by exerting direct in situ immunomodulating effects, in addition to their ability to provide a potential source for remyelination and neuroregeneration. Preliminary results from our laboratory indicate that intravenous or intracerebral/intraventricular injection of bone marrow derived stromal cells could differentiate in neuronal/glial cells and suppress the clinical signs of chronic EAE. Both bone marrow and neuronal stem cells may therefore have a therapeutic potential in MS. It seems that future treatment strategies for MS should combine immunomodulation with neuroprotective modalities to achieve maximal clinical benefit.

Publication types

  • Review

MeSH terms

  • Humans
  • Immunologic Factors / therapeutic use*
  • Multiple Sclerosis / therapy*
  • Neuroprotective Agents / therapeutic use*
  • Stem Cell Transplantation*


  • Immunologic Factors
  • Neuroprotective Agents